• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Centers for Medicare and Medicaid Services (CMS)

Abbott wins Medicare reimbursement for FreeStyle Libre 2

September 1, 2020 By Sean Whooley

Abbott logo updated

Abbott (NYSE:ABT) announced today that its next-generation FreeStyle Libre 2 iCGM is now available to Medicare patients. The integrated continuous glucose monitoring (iCGM) system met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS), making it accessible to all Medicare patients with diabetes who meet the […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: abbott, Centers for Medicare and Medicaid Services (CMS)

Abbott, Medtronic go head-to-head at ADA conference

June 15, 2020 By Nancy Crotti

Major medtech companies vied for the biggest news splash at this year’s annual meeting of the American Diabetes Association, announcing promising results from studies of patients who used their latest diabetes technology. The virtual 80th Annual American Diabetes Association Virtual Scientific Sessions, which runs through Tuesday, so far has featured news out of Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) and several smaller […]

Filed Under: Auto-injectors, Big Data, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Research & Development Tagged With: abbott, American Diabetes Association, Centers for Medicare and Medicaid Services (CMS), dariohealth, Medtronic, One Drop, Tandem Diabetes Care

Mylan agrees to settle SEC EpiPen probe for $30 million

July 31, 2019 By Nancy Crotti

Mylan logo - updated

Mylan (NSDQ:MYL) is nearing a $30 million settlement with the Securities and Exchange Commission (SEC) over an investigation involving the company’s EpiPen auto-injector and the Medicaid drug rebate program. The SEC probe was announced in 2016, shortly after Mylan agreed to pay $465 million to the U.S. Department of Justice to settle claims that it […]

Filed Under: Auto-injectors, Business/Financial News, Legal News, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS), epipen, Mylan, Securities and Exchange Commission (SEC), U.S. Department of Justice

Ocular Therapeutix’s ophthalmic device gains Medicare coverage early

July 26, 2019 By Nancy Crotti

Ocular Therapeutix logo

Ocular Therapeutix (NSDQ:OCUL) said today that the Centers for Medicare and Medicaid Services has assigned a specific and permanent reimbursement J-code for its Dextenza ophthalmic insert, which is approved for the treatment of ocular inflammation and pain following ophthalmic surgery. The code assigned to Dextenza through the Healthcare Common Procedure Coding System will become effective […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Pain Management, Uncategorized, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS), Ocular Therapeutix

Intersect ENT wins preliminary CMS reimbursement code

April 30, 2019 By Nancy Crotti

Intersect ENT updated

Shares in Intersect ENT (NSDQ:XENT) got a boost yesterday on news that the Centers for Medicare and Medicaid Services (CMS) had assigned the company’s Sinuva corticosteroid-eluting sinus implant a preliminary J-code. Intersect ENT stock, which had been bumping along just under $30 per share last week, jumped to $33.13 per share at Monday’s market open, […]

Filed Under: Drug-Device Combinations, Featured, Implants, Uncategorized Tagged With: Centers for Medicare and Medicaid Services (CMS), Intersect ENT Inc., SVB Leerink

Insulet lands Medicare Part D coverage for Omnipod insulin delivery system

January 8, 2018 By Sarah Faulkner

Insulet Omnipod

The Centers for Medicare and Medicaid Services issued guidance today noting that Insulet‘s (NSDQ:PODD) Omnipod tubeless insulin delivery device can be covered by the Medicare Part D prescription drug program. The Billerica, Mass.-based company estimated that its latest reimbursement win extends access to the Omnipod system to 450,000 people with Type I diabetes across the U.S. […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS), Insulet

Abbott nabs CMS reimbursement for FreeStyle Libre continuous glucose monitor

January 4, 2018 By Sarah Faulkner

Abbott

Abbott (NYSE:ABT) said today that its FreeStyle Libre continuous glucose monitor is now available to Medicare patients, after the Centers for Medicare & Medicaid Services determined that the device can be classified as a therapeutic CGM. The FreeStyle Libre is designed to read glucose levels through a sensor worn on the back of a person’s upper […]

Filed Under: Diabetes, Featured, Patient Monitoring, Wall Street Beat Tagged With: abbott, Centers for Medicare and Medicaid Services (CMS), DexCom Inc.

Report: Drugmakers may have ducked $1.3B in Medicaid rebates

December 21, 2017 By Sarah Faulkner

CMS

Without calling out any drug companies by name, the U.S. Dept. of Health and Human Services’ Office of Inspector General revealed this week that 10 potentially misclassified drugs may have resulted in $1.3 billion in lost rebates to Medicaid between 2012 and 2016. The issue of ducking rebates came to the public’s attention earlier this […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS)

Mylan inks $465m settlement with DOJ over EpiPen Medicaid classification

August 17, 2017 By Sarah Faulkner

Mylan

Mylan (NSDQ:MYL) said today that it inked a $465 million deal with U.S. Dept. of Justice to settle claims that it misclassified its EpiPen allergy auto-injector device with the Medicaid Drug Rebate Program. In October last year, The Centers for Medicare & Medicaid Services said that Mylan had been overcharging Medicaid for its EpiPen device for years, […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS), Mylan, Sanofi-Aventis

Kentucky doc gets jail time for bad opioid prescription habits & Medicaid fraud

June 7, 2017 By Sarah Faulkner

Prescription drugs

Dr. George Kudmani, an OB/GYN from Kentucky, was sentenced to 4 years in prison this week after a federal jury ruled that he was guilty of inappropriately doling out opioids and Medcaid fraud. The jury found Kudmani guilty of 19 counts of unlawful distribution of controlled substances and 8 counts of health care fraud. After Kudmani serves his […]

Filed Under: Featured, Hospital Care, Legal News, Pharmaceuticals, Women's Health Tagged With: Centers for Medicare and Medicaid Services (CMS)

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS